Skip to main content

OPtimizing TArgets and Therapeutics In high risk and refractOry Multiple Myeloma

Objective

Multiple Myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of the OPTATIO consortium to seek out novel strategies for the development of novel diagnostic and therapeutic options. The MM pathogenesis involves not only genetic changes within the tumour cells but also the emergence of supportive conditions by the bone marrow microenvironment (BMM). To target the essential components of this support system, it is the goal of the project to establish preclinical in vitro and in vivo models of MM that include functionally relevant elements of the BMM. The OPTATIO consortium will therefore analyse clinical data to correlate the presence of particular MM-BMM interactions with the pathogenesis of MM, with its intrinsic therapy resistance as well as with disease relapse due to the development of acquired drug resistance. These correlative data will be validated using autologous MM-BMM co-culture assays and reverse translated into in vitro screening and in vivo models, which will be subsequently used to develop lead compounds that target myeloma cells within their microenvironment.
The clinical expertise of several oncological divisions, the research experience of academic laboratories and the pharmaceutical know-how of small and medium sized enterprises as well as biotech industry joined their efforts within the OPTATIO consortium to drive this important development and to ensure translation towards clinical trials.
Expected impacts of the project include establishment of better diagnostics, new drug screening approaches for MM and novel personalised therapies based on individual ex vivo phenotyping leading to reduced patient mortality. Since envisaged drug screening methods are applicable to other areas of research and development, the project results will open new markets for industry partners in the fields of drug discovery and pharmaceutical development of products and services for personalized medicine.

Field of science

  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance

Call for proposal

FP7-HEALTH-2011-two-stage
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

MEDIZINISCHE UNIVERSITAT INNSBRUCK
Address
Christoph Probst Platz 1
6020 Innsbruck
Austria
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 510 700
Administrative Contact
Wolfgang Willenbacher (Dr.)

Participants (11)

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Germany
EU contribution
€ 287 956,80
Address
Josef-schneider-strasse 2
97080 Wurzburg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Melanie Bauer (Ms.)
Masarykova univerzita
Czechia
EU contribution
€ 279 600
Address
Zerotinovo Namesti 9
60177 Brno Stred
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Sabina Sevcikova (Dr.)
UNIVERSITA DEGLI STUDI DI BARI ALDO MORO
Italy
EU contribution
€ 262 800
Address
Piazza Umberto I 1
70121 Bari
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Domenico Ribatti (Prof.)
DEL-PESTI CENTRUMKORHAZ-ORSZAGOS HEMATOLOGIAI ES INFEKTOLOGIAI INTEZET
Hungary
EU contribution
€ 144 000
Address
Nagyvarad Ter 1
1097 Budapest
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Tamás Masszi (Dr.)
VEREIN ZUR FOERDERUNG DER KREBSFORSCHUNG IN TIROL
Austria
EU contribution
€ 190 800
Address
Innrain 66
6020 Innsbruck
Activity type
Research Organisations
Administrative Contact
Richard Greil (Prof.)
KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
Germany
EU contribution
€ 319 792,50
Address
Breisacher Strasse 117
79106 Freiburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Michael Kubbutat (Dr.)
VICHEM CHEMIE KUTATO KFT
Hungary
EU contribution
€ 239 760
Address
Hermann Otto Utca 15
1022 Budapest
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Zoltán Dobai (Mr.)
ONCOTYROL-CENTER FOR PERSONALIZED CANCER MEDICINE GMBH
Austria
EU contribution
€ 293 040
Address
Karl Kapferer Strasse 5/3
6020 Innsbruck
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Lukas A. Huber (Prof.)
PHARMAMAR, S.A.
Spain
EU contribution
€ 239 880
Address
Avda. De Los Reyes , Poligono Industrial La Mina 1
28770 Colmenar Viejo (Madrid)
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Elena Calleja (Ms.)
THE BINDING SITE GMBH
Germany
EU contribution
€ 37 200
Address
Robert-bosch-straße 2A
68723 Schwetzingen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Silvia Kirchner (Dr.)
CENTER OF EXCELLENCE IN MEDICINE AND IT GMBH
Austria
EU contribution
€ 194 000
Address
Karl Kapferer Strasse 5
6020 Innsbruck
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Manuela Bock Bartl (Ms.)